ADDvise receives allocation decision worth approximately SEK 72 million
ADDvise Group’s subsidiary Hettich Labinstrument AB has received an allocation decision from Region Stockholm worth approximately SEK 72 million. The allocation decision involves the delivery of blood specimen collection equipment over a four-year period, commencing in May 2025. The allocation decision can be appealed up until December 20, 2024. For further information, please contact: Staffan Torstensson, CEO+46 704 33 20 19staffan.torstensson@addvisegroup.se Important information This information is information that ADDvise Group AB is required to disclose under the EU